The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.

KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This is a multi-center, single-arm, open-label, early exploratory clinical study. The objective of this study is to evaluate the safety and preliminary efficacy of KSVCBD injection in AQP4-positive Neuromyelitis Optica Spectrum Disorder

NCT Number	NCT07592754
Lead Sponsor	Chinese PLA General Hospital
Conditions	Neuromyelitis Optica Spectrum Disease (NMOSD)
Enrollment	18 participants
Start Date	2026-05-15
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-18